This Superb Cannabis Stock Is All You’ll Ever Need

Aphria Inc (TSX:APHA)(NYSE:APHA) is one of the best pot stocks that you can add to your investment portfolio as a cannabis investor. Here’s why.

Cannabis stocks have fallen.
You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

The cannabis industry has had an interesting year so far. The industry expected to boom after Canada’s legalization of recreational marijuana, and the pot industry caught everybody by surprise. As legalization was underway last year, investors flocked to cannabis company stocks, and they skyrocketed.

Early investors became rich in a matter of months, and things looked brighter than ever — until they weren’t.

The share prices of pot stocks increased, but almost all of the substantial pot companies are still struggling to maintain profitability. The most promising pot producers underperformed, and the CannTrust scandal rattled the industry.

Pot stock prices declined by 50%. While the skepticism of the industry being another dot-com bubble is not true, pot stocks have indeed struggled over the past several months. The last few months have been crucial for the industry. The performances of companies during this time show us which cannabis stocks will be able to compete and which ones might fail.

Aphria (TSX:APHA)(NYSE:APHA) is quickly becoming a favourite among marijuana investors. The current opinion on Aphria is a massive difference, because some argued that Aphria stock was worth $0 just last year. At $7.55 per share while I write this, I think that Aphria is a pot stock you should consider adding to your portfolio.

Aphria is not coming slow

The legalization of adult-use marijuana in Canada was a critical factor in the rise of Aphria as an affluent part of the weed industry. In the latest quarter, Aphria’s revenue grew to an impressive $18.5 million — an increase of almost 160% from Q4 2018. More than 60% of Aphria’s total revenue came from the recreational marijuana market in Canada.

The current share price, in my opinion, is possibly a heavily discounted price for Aphria. As an investor, you need to look at the performance of the company.

Aphria is among the most profitable pot companies in the industry. A cost-conscious pot producer, the company is catering to the industry while cutting down on production costs.

Aphria continues to report profitable operations. Let us take a look at Marigold Projects. Marigold is a subsidiary, 49% owned by Aphria. The subsidiary opened a retail store on the five-acre marijuana farm of the company. The retail shop includes a smoking lounge for customers. As small a move as it may seem, it makes Aphria appear more attractive to customers.

The cost of goods Aphria sells is at an industry low of $2.35 per gram. The company’s sales keep on growing with the rising demand. Both of these factors mean Aphria is becoming increasingly profitable. The import-export regulations on recreational marijuana in Canada are not making it easy for pot producers to get the right demand/supply balance.

Pot producers need to compete with each other in production efficiency to come out on top, and Aphria is beating all of the competitors.

Foolish takeaway

It is difficult to accurately predict how good the outlook for the pot industry will be in the future, or where Aphria will stand in the long run. What I can say with confidence about Aphria is that the pot company is well positioned to grow even further. Aphria experienced massive setbacks last year, but the company has come a very long way since.

While I feel a little adventurous in expressing my opinion so blatantly, but I think that Aphria could be the only cannabis stock you will ever need.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Adam Othman has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »